DOCSLIB.ORG

Driving More Affordable, Accessible and Effective Care

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Driving More Affordable, Accessible and Effective Care Driving More Affordable, Accessible and Effective Care Larry Merlo President & Chief Executive Officer Forward-looking Statements; Non-GAAP Measures During today’s presentation, we will make forward-looking statements within the meaning of the federal securities laws. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our SEC filings, including the risk factors section and cautionary statement disclosure in those filings. During this presentation, we will also use some non-GAAP financial measures when talking about our company’s performance, including free cash flow, cash available to enhance shareholder value and Adjusted EPS. In accordance with SEC regulations, you can find the definitions of these non-GAAP items, as well as reconciliations to comparable GAAP measures, on the investor relations portion of our website. 2 Key Accomplishments in 2016 Strong financial performance Enhanced Long-Term Care Adjusted EPS growth of ~12%; Introduced pilot programs to improve Free Cash Flow of $6.9B patient care Successful PBM selling season Completed Target integration $7.8B gross new business for 2017; Integrated Target pharmacies and clinics client retention of ~97% Effectively managed trend Advanced front store strategies Delivered profitable sales through Achieved client drug trend of only 3.3% enhanced offerings, personalization through September and digital capabilities Superior Specialty growth Plan to reaccelerate growth Includes new partnerships with payors, Dispensed revenue growth of ~19%, new PBM products, cost savings initiative continuing to outpace market and capital deployment 3 Refer to endnotes for additional information. Driving More Affordable, Accessible and Effective Care Affordable Accessible Effective Cost management Unmatched breadth of Analytics capabilities solutions to drive real assets to connect with and clinical programs savings in the health patients fully across to help drive adherence care economy the care continuum and health outcomes 4 Driving More Affordable, Accessible and Effective Care Affordable Accessible Effective Cost management Unmatched breadth of Analytics capabilities solutions to drive real assets to connect with and clinical programs savings in the health patients fully across to help drive adherence care economy the care continuum and health outcomes 5 Today’s Key Takeaways Driving More Affordable, Accessible and Effective Care Driving Outcomes In an era of rising costs, we are the optimal partner to deliver savings and Savings and help improve outcomes for health care stakeholders Providing the Front Pharmacy has the highest frequency of interaction and our unmatched Door and the Last Mile patient touch points across the enterprise help shape behavior Best Partner for PBMs We can partner with all PBMs and health plans, leveraging our and Health Plans enterprise assets and capabilities to meet their individual needs Integrated Our exclusive programs are seamlessly integrated through our Health Pharmacy Care Engagement Engine, providing better member experience and results Positioned for L-T Maximize shareholder value with an enterprise mindset; generate strong Enterprise Growth cash flow and employ a disciplined approach to capital allocation 6 Today’s Agenda Topic Speaker Maximizing Shareholder Value With an Enterprise Mindset Dave Denton Delivering Value for All Health Care Stakeholders Larry Merlo Meeting the Health Care Challenges of Tomorrow Jon Roberts Leading the Evolution of the Specialty Model Alan Lotvin Capitalizing on the Retailization of Health Care Helena Foulkes 7 Endnotes Slide 3 1. Refer to non-GAAP tab in Analyst Day presentation book or the Investor Relations portion of the CVS Health website for Adjusted EPS reconciliation for the year ending December 31, 2016 and the year ended December 31, 2015. 2. Refer to non-GAAP tab in Analyst Day presentation book or the Investor Relations portion of the CVS Health website for Free Cash Flow reconciliation for the year ending December 31, 2016 and the year ended December 31, 2015. 3. Adjusted EPS growth and Free Cash Flow are based on midpoints of 2016 guidance. 4. Gross new business revenue excludes Medicare Part D SilverScript individual products. 5. Client retention rate is defined as: 1 less (projected 2017 lost revenues from any known terminations plus annualization of any mid-year 2016 terminations, divided by estimated 2017 PBM revenues) expressed as a percentage. Both terminations and PBM revenues exclude Medicare Part D SilverScript individual products. 6. Client drug trend is the measure of growth in prescription spending per member per month. Trend calculations take into account the effects of drug price, drug utilization and the mix of branded versus generic drugs. Trend figures cited are for commercial cohort (health plans and employers). Trend is 2016 YTD through September and is reported net of rebates. 7. Specialty growth defined as 2016 forecasted dispensed revenue growth for specialty products vs. 2015. 8 Maximizing Shareholder Value With an Enterprise Mindset Dave Denton Executive Vice President & Chief Financial Officer Agenda Strong Record of Execution Marketplace Misconceptions 2017 Guidance Review Solid Long-Term Outlook 2 Continuing Focus on Maximizing Shareholder Value Productive Long-Term Growth Generating Enhanced Significant Shareholder Value Free Cash Flow Optimizing Capital Allocation 3 Key Financial Accomplishments of 2016 Adjusted Earnings Per Share • Delivering strong Adjusted EPS growth of ~12% Prescription and • Enterprise script and claim growth of ~19%, including the Claim Growth additions of Omnicare and Target pharmacies • Successfully refinanced debt to take advantage of Refinanced Debt favorable interest rates Free Cash Flow • Generating significant free cash flow of nearly $7 billion • Returning ~$6 billion to shareholders through dividends Shareholder Value and share repurchases 4 Refer to endnotes for additional information. Solid Performance Expected in 2016 Full-Year 2016 Net Revenue Growth 16.0% to 16.5% Adjusted EPS $5.77 to $5.83 Year-Over-Year Growth 11.75% to 13.0% Free Cash Flow $6.8 to $7.0 billion Year-Over-Year Growth Up 5% to 8% GAAP Diluted EPS $4.82 to $4.88 5 Refer to endnotes for additional information. Meeting Enterprise Growth Targets Through 2016 … Operating Profit Adjusted EPS ($, billions) ($) 5.77 10.5 to to 5.83 ~10% 10.6 ~14% CAGR CAGR 8.0 3.96 2013 2014 2015 2016E 2013 2014 2015 2016E 6 Refer to endnotes for additional information. … And Generating Significant Free Cash Flow Key drivers: Free Cash Flow ($, billions) • Enterprise prescription dispensing 6.9 share gains 57% • Specialty pharmacy 4.4 • Improved purchasing • Working capital management 2013 2016E Free cash flow has increased by $2.5 billion over the last three years Refer to endnotes for additional information. 7 Committed to Maintaining a Healthy Balance Sheet Adjusted Debt-To-EBITDA • Committed to returning to 2.7x targeted leverage ratio 4.0 3.39 3.02 – Driven mostly by EBITDA growth and debt repayments 3.0 2.66 Target = 2.70 – Modified long-term debt 2.0 2.39 structure in 2014 and 2016 to take advantage of favorable interest rates 1.0 '13 '14 '15 '16E Focused on maintaining BBB+ credit rating 8 Refer to endnotes for additional information. Well-Laddered Debt Maturities Remain Core to Strong Balance Sheet Debt Maturity Profile (Bonds) 3.5 ($, billions) 3.5 3.1 2.8 2.8 2.4 1.8 1.3 0.9 0.9 0.7 0.8 0.4 0.4 0.0 0.1 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2035 2039 2041 2043 2045 Debt refinancing reduced interest expenses by ~$50 million 9 Efficient Cash Deployment 2014 Through 2016 Focused on Three Pillars Cash Available for Enhancing Shareholder Value $32 billion Dividends Acquisitions Share Repurchases and Ventures Nearly $5 billion More than $13 billion returned to Nearly $14 billion in in value-creating shareholders acquisitions repurchases 10 Solid History of Enhancing Returns Using All Three Pillars for Efficient Cash Deployment Annual Dividend Acquisitions Share Repurchases Per Share and Ventures ($, billions) ($) Jan ’14 Jul ’14 24% Coram Red Oak 5.0 CAGR Sourcing 4.5 1.70 4.0 1.40 Sep ’14 1.10 Aug ’15 Navarro Omnicare Dec ’15 '14 '15 '16 '14 '15 '16E Target 11 2017 Will See a Dividend Increase of 18% and Further Share Repurchases Annual Dividend Per Share ($) more than 18% 2.00 1.70 billion 1.40 $18 1.10 authorized and remaining for share repurchase '14 '15 '16 '17E 12 2017 Will See a Dividend Increase of 18% and Further Share Repurchases Annual Dividend Share Repurchases Per Share ($, billions) ($) 18% 5.0 5.0 4.5 2.00 4.0 1.70 1.40 1.10 '14 '15 '16 '17E '14 '15 '16E '17E Nearly $7 billion expected to be returned to shareholders in 2017 13 Agenda Strong Record of Execution Marketplace Misconceptions 2017 Guidance Review Solid Long-Term Outlook 14 MYTH #1 IF REBATES DISAPPEARED, PBM PROFITS WOULD SUBSTANTIALLY DROP 15 FACT #1 REBATES ARE BUT ONE OF MANY ELEMENTS OF PBM PROFITABILITY 16 FACT #1: Rebates Are but One of Many Elements of PBM Profitability A Number of Elements Drive PBM Profitability • Manage to overall profitability margin more than • Clients’ contracts structured differently, per client needs • Profitability elements include: 90% - Margin on: • Dispensing mail and specialty pharmacy scripts of rebates overall • Network pharmacy benefit management passed to clients - Clinical programs
Load more

Recommended publications
  • TC-017 Butterfield, Dawn (National Community Pharmacy Association)
    Peter Mucchetti, Chief Healthcare and Consumer Products Section, Antitrust Division Department of Justice 450 Fifth Street NW, Suite 4100 Washington, DC 20530 December 13, 2018 Dear Judge Leon: Thank you so much for inviting or allowing comments on the proposed CVS/Aetna merger. We (pharmacy owners/pharmacists) were not happy when our own organization - NCPA - National Community Pharmacy Association was referenced in the Congressional Hearing on this merger earlier in the year that "we were fine" with the merger as expressed by Tom Moriarty - CVS General Counsel to the Congressional Committee. This most assuredly is NOT the case I can assure you. However that was communicated - and not clarified by our association is an issue we are all still highly upset about as I believe that was the time to publicly state our vehement opposition to this merger. In other words, a major ball was dropped and a bell was rung that couldn't be unrung. That being said - we, as business owners and professionals don't know how we can state our issues - which are numerous and we were being told by virtually everyone that the merger is a "done deal" as the FTC and DOJ didn't have an issue with it. I hope you receive communication from people who took the time to do so. Some people are frozen and/or feel defeated as they believe there's nothing to stop this train and have given up. I can say with certainty that for every letter from a pharmacist/pharmacy owner/pharmacy professor - there were 1000 that went along with it! I'm enclosing some material you may already have, but the infographic on the states shows to the extent of what can happen when your competition sets YOUR price.
    [Show full text]
  • CVS Pharmacy Network
    Participating Retail Pharmacies The following list shows the major chain pharmacies and affiliated groups of independent community pharmacies that accept your prescription benefit ID card. In addition to these, most independent pharmacies nationwide also take part in your prescription program. To find out if a pharmacy not listed here accepts your card, call the pharmacy directly. A C (continued) G (continued) A & P Pharmacy CVS Caremark Specialty Pharmacy Giant Eagle Pharmacy AAP / United Drugs CVS/Longs Giant Pharmacy Accredo Health Group, Inc. CVS/pharmacy Good Neighbor Pharmacy ACME Pharmacy Albertson’s Pharmacy American Pharmacy Cooperative / D H American Pharmacy Network Solutions Dahl’s Pharmacy Haggen Pharmacy American Home Patient Dierbergs Pharmacy Hannaford Food & Drug American Pharmacy Dillon Pharmacy Happy Harry’s Ameridrug Pharmacy Discount Drug Mart Harmons Pharmacy Apria Healthcare, Inc. Doc’s Drugs Harps Pharmacy Doctor’s Choice Pharmacy Aurora Pharmacy Harris Teeter Pharmacy Dominick’s Pharmacy Harvard Drug Drug Town Pharmacy Harvard Vanguard Medical Association B Drug Warehouse Harveys Supermarket Pharmacy Baker’s Pharmacy Drug World H-E-B Pharmacy Bartell Drugs Drugs for Less Health Mart Basha’s United Drug Duane Reade HealthPartners Bel Air Pharmacy Duluth Clinic Hen House Pharmacy Bi-Lo Pharmacy Henry Ford Pharmacy Bi-Mart Pharmacy Hi-School Pharmacies Biggs Pharmacy E Hilander Pharmacy Bioscrip Pharmacy EPIC Homeland Pharmacy Bloom Pharmacy Eaton Apothecary Horton & Converse Brookshire Brothers Pharmacy Econofoods
    [Show full text]
  • Joint Proxy Statement of CVS Corporation and Caremark Rx, Inc
    MERGER PROPOSED YOUR VOTE IS VERY IMPORTANT The boards of directors of CVS Corporation and Caremark Rx, Inc. have each approved a merger agreement which provides for the combination of the two companies in a transaction structured as a merger of equals. The boards of directors of CVS and Caremark believe that the combination of the two companies will be able to create substantially more long-term stockholder value than either company could individually achieve. Following the completion of the merger, Caremark will be a wholly owned subsidiary of CVS and Caremark stockholders will own approximately 45.5% of the outstanding common stock of the combined company and CVS stockholders will own approximately 54.5% of the outstanding common stock of the combined company, in each case, on a fully diluted basis. CVS Corporation is referred to as CVS and Caremark Rx, Inc. is referred to as Caremark. The combined company will be named CVS/Caremark Corporation and the shares of the combined company will be traded on the New York Stock Exchange, or the NYSE, under the symbol CVS . If the merger is completed, Caremark s stockholders will receive 1.670 shares of common stock of CVS/Caremark, for each share of Caremark common stock that they own immediately before the effective time of the merger. Caremark stockholders will receive cash for any fractional shares which they would otherwise receive in the merger. Caremark stockholders will also receive a one-time special cash dividend in the amount of $2.00 per share of Caremark common stock held by each such holder on a record date to be set by the Caremark board of directors, which dividend will be conditioned on the completion of the merger and will be paid at or immediately following the effective time of the merger.
    [Show full text]
  • CVS Digital Capabilities
    Digital Capabilities Connecting members, patients and customers to our services anytime, anywhere. Table of Contents Our Digital Strategy ............... 4 Helping people save CVS Caremark® ...................... 6 time, save money CVS Specialty® ....................... 8 Omnicare® and and stay healthy. Medicare Part D ................... 10 CVS Pharmacy® and Here at CVS Health, we’re reinventing pharmacy to help people on their CVS MinuteClinic™ ............... 12 path to better health. Our commitment to digital innovation is one way we’re putting our purpose into action. Front Store ............................ 14 Throughout all of our service brands, we offer members, patients and customers a suite of digital tools that make managing their health more accessible, more intuitive and more integrated across all our channels. Moving forward, we’ll continue to transform the future of health care by redefi ning convenience and improving the health outcomes of millions of people. 2 3 Build Develop the ultra-convenient, fully integrated pharmacy Our experience only CVS Health can provide across our service brands (CVS Pharmacy, Digital CVS MinuteClinic, CVS Caremark, Strategy CVS Specialty and Omnicare). Digital tools are Personalize transforming the way Provide individualized customer consumers shop and interactions, leveraging data across manage their health care. all touch points to help members, patients and customers on their We’re responding to path to better health. these changing needs by differentiating the customer experience through three Innovate strategic pillars. Harness critical digital trends through rapid testing/learning/ iteration and third-party collaboration at the CVS Health Digital Innovation Lab. 4 5 Member Set Up Print Rx History Easy Refill Makes budgeting and tax prep Offers members a simple way Early Registration easier by allowing members to to refill by scanning the barcode Allows members to register and print a list of prescription costs.
    [Show full text]
  • The Power Of
    A DSN SPECIAL REPORT n 2012, DSN presented an in-depth report on CVS Caremark’s integrated pharmacy business model — part big retail pharmacy chain, part big PBM, part big retail clinic operator — and the innova- tive products and solutions that were coming out of the organization, particularly where the three parts of Ithe business came together, its “integration sweet spots,” as company executives referred to them. It was clear at the time that the company had emerged as a “category of one,” which was the cover theme of that special issue. Now, a year later, as the company completes its 50th year in business and the country awaits a period of change in health care unlike anything seen in at least that time, CVS Caremark executives are quite confident that its unique hybrid structure and its ability to leverage the three core parts of its business — either individually or together, in varying combinations to serve a multitude of needs — aligns more effectively with the long-term trends in health care and puts the company in a unique position at a singular moment in history. In an exclusive interview with DSN, CVS Caremark president and CEO Larry Merlo talked about what that means, why it’s important to both public and private pay- ers of all sizes, health plans, patients and providers, as well as how the company is using behavioral economics and predictive analytics to more effectively engage clients and customers and how they are building new clinical capabilities to address the new models of care, new cus- tomers and new quality standards that will guide the new payment models that will emerge through health reform.
    [Show full text]
  • Participating Retail Pharmacies
    Participating Retail Pharmacies The following list shows the major chain pharmacies and affiliated groups of independent community pharmacies that accept your prescription benefit ID card. In addition to these, most independent pharmacies nationwide also take part in your prescription program. To find out if a pharmacy not listed here accepts your card, call the pharmacy directly. A D H A & P Pharmacy Dahl’s Pharmacy Haggen Pharmacy AAP / United Drugs Dierbergs Pharmacy Hannaford Food & Drug Accredo Health Group, Inc. Dillon Pharmacy Happy Harry’s ACME Pharmacy Discount Drug Mart Harmons Pharmacy Albertson’s Pharmacy Doc’s Drugs Harps Pharmacy American Pharmacy Cooperative / Doctor’s Choice Pharmacy Harris Teeter Pharmacy American Pharmacy Network Solutions Dominick’s Pharmacy Harvard Drug American Home Patient Drug Town Pharmacy Harvard Vanguard Medical Association American Pharmacy Drug Warehouse Harveys Supermarket Pharmacy Apria Healthcare, Inc. Drug World H-E-B Pharmacy Aurora Pharmacy Drugs for Less Health Mart Duane Reade HealthPartners Duluth Clinic Hen House Pharmacy B Henry Ford Pharmacy Baker’s Pharmacy Hi-School Pharmacies Bartell Drugs E Homeland Pharmacy Basha’s United Drug EPIC Horton & Converse Bel Air Pharmacy Eaton Apothecary Hy-Vee Pharmacy Bi-Lo Pharmacy Econofoods Bi-Mart Pharmacy Biggs Pharmacy I Bioscrip Pharmacy F IHC Health Center Bloom Pharmacy Fagen Pharmacy Infusion Partners Brookshire Brothers Pharmacy Fairview Ingles Pharmacy Brookshire Pharmacy Family Care Bruno’s Food and Pharmacy Family Pharmacy Farm Fresh
    [Show full text]
  • CVS 2755 Hollywood Ave Shreveport LA
    CVS OFFERING MEMORANDUM 2755 Hollywood Avenue| Shreveport, LA ™ Representative Photo CVS, Shreveport, LA | 1 ™ Representative2 | Offering Photo Memorandum contents 04 investment highlights 05 financial OVERVIEW 06 tenant overview 10 area OVERVIEW exclusively listed by rahul chhajed Senior Associate [email protected] DIR (949) 432-4513 MOB (818) 434-1106 LIC # 01986299 (CA) michael moreno Senior Associate [email protected] DIR (949) 432-4511 MOB (818) 632-1497 LIC # 01982943 (CA) aron cline SVP & Senior Director [email protected] DIR (949) 432-4509 MOB (818) 632-0233 LIC # 01904371 (CA) Beau j. box BROKER OF RECORD LIC # BROK.0000072286.A-ACT CVS, Shreveport,Representative LA | 3Photo executive summary Representative Photo investment highlights • 10,908 SF Freestanding CVS (BBB+ S&P) on Approximately 1.57 Acres • Primary Lease Term Through 12/31/18 with Four Renewal Options Remaining • Hard Corner at Signalized Intersection • Excellent Signage and Visibility • ± 140,000 residents within a 5-mile radius • Building is situated on a ± 1.57 AC lot 4 | Offering Memorandum financial overview CVS Annualized Operating Data 2755 Hollywood Avenue Monthly Rent Annual Rent Cap Rate Increases Shreveport, LA 71108 Current - 12/31/2018 $25,320.93 $303,851.10 20.26% 1.70% List Price .................................................................................. $1,500,000 Option 1 $25,775.43 $309,305.10 20.60% 1.70% Option 2 $26,229.93 $314,759.10 20.95% 1.70% CAP Rate - Current ....................................................................... 20.26% Option 3 $26,684.43 $320,213.10 21.31% 1.70% Gross Leasable Area ............................................................± 10,908 SF Option 4 $27,138.93 $325,667.10 21.67% 1.70% Lot Size .................................................................................
    [Show full text]
  • Statement for the Record: the National Community Pharmacists Association (NCPA)
    Statement for the Record: The National Community Pharmacists Association (NCPA) United States House Subcommittee on Regulatory Reform, Commercial and Antitrust Law Hearing: “Competition in the Pharmaceutical Supply Chain: The Proposed Merger of CVS Health and Aetna” February 27, 2018 Chairman Marino and Ranking Member Cicilline, and Members of the Subcommittee: Thank you for conducting this hearing on competition in the pharmaceutical supply chain and on the pending merger of CVS Health and Aetna Inc. that is currently under review at the Antitrust Division of the Department of Justice (“DOJ”). NCPA represents America’s community pharmacists, including the owners of more than 22,000 independent community pharmacies. Together they represent an $80 billion healthcare marketplace and employ more than 250,000 individuals on a full or part-time basis. These pharmacies dispense approximately 40% of all community pharmacy prescriptions and are often located in underserved rural or urban areas. In this statement, NCPA will highlight how increased consolidation in the healthcare industry may be contributing to higher costs and negatively impacting patient choice. NCPA will also address several potential issues and pose questions related to the CVS Health/Aetna Inc. merger and the broader implications on the healthcare industry. NCPA recommends that the proposed merger between CVS Health and Aetna Inc. be closely examined to determine whether this transaction will lead to lower quality/fewer options for patients, higher costs, and less competition in the healthcare market. Potential Implications on Pharmacy Choice for Patients The proposed CVS Health/Aetna Inc. merger raises several questions regarding its impact on pharmacy choice for patients.
    [Show full text]
  • Walgreens: Strategic Evolution1
    Walgreens: Strategic Evolution1 America’s largest drugstore chain, Walgreens, had 8,210 locations by 2011, including 7,761 drugstores. Almost 75 percent of Americans lived within five miles of a Walgreens pharmacy, and more than 6 million customers were served each day. Walgreens issued more than 800 million prescriptions annually, representing 20 percent of the U.S. market. Its online business, Walgreens.com, had almost 17 million visitors per month. Walgreens’ strategy had evolved for more than a century in business. By 2012, the company faced a number of major strategic questions, including international expansion and a changing health care environment. History of Pharmacy2 People have been trying to create remedies for illnesses and ailments since the beginning of time, but most historians credit Babylon with the first organized apothecary. This was followed by the Romans, who created a system of pathology and therapy that became standards for Western medicine for more than 1,000 years. For the most part, though, pharmacy remained a sketchy and shadowy business for centuries, practiced by (among others) witch doctors and alchemists. Advances in medicine and the Renaissance era led to more structured and scientific approaches. In 1240, German Emperor Frederick II issued a proclamation establishing the practice of pharmacy along three tenets: (1) separation of the pharmaceutical profession from the medical profession; (2) official supervision (regulation) of pharmacy; and (3) “obligation to prepare drugs reliably, according to skilled art, and in a uniform, suitable quality.”3 Public pharmacies and university training began spreading throughout Europe. 1 This case was written by John S.
    [Show full text]
  • NCPDP NPI Name 0353780 1962446211 CVS PHARMACY 0400363 1235114208
    NCPDP NPI Name 0353780 1962446211 CVS PHARMACY 0400363 1235114208 COLLEGE HILL HEALTH MART 0400387 1275603359 ALLCARE PHARMACY 0400919 1508972167 MEDIC PHARMACY INC 0413548 1073530465 WAL-MART PHARMACY 0417558 1013956499 SAVON PHARMACY 0422597 1356474449 WALGREENS #10418 0423878 1316213168 ROBERTSON'S NORTH HEIGHTS PHARMACY 0424046 1659629152 CVS PHARMACY #10019 0571782 1629012075 CVS PHARMACY 0619962 1841205192 WALGREENS #9979 1074397 1528162484 CVS PHARMACY 1089526 1598765570 AXIUM HEALTHCARE PHARMACY, INC 1406493 1588779516 RIVERVIEW PHARMACY 1531703 1235144379 WALGREENS #3442 1535371 1619946746 UNIVERSITY RETAIL PHARMACY 1623809 1487977195 KEDO, LLC D/B/A/ VALUMED PHARMACY 1702895 1578645362 GREENHAW PHARMACY INC 1907116 1164448957 HEADRICKS DRUG STORE 1918119 1376561852 WAL-MART PHARMACY 10-0278 1919159 1528085867 WAL-MART PHARMACY 10-0448 1919426 1437176773 WAL-MART PHARMACY 1923920 1154348415 WAL-MART PHARMACY 10-116 1927815 1528051836 NIELSENS PHARMACY 1928552 1932116860 WALGREENS #4304 1930874 1588679757 WALGREENS #7166 1930999 1114932381 WALGREENS #7426 1931472 1265538664 PMO PHARMACY MANAGEMENT SHREVEPORT 1931864 1235145731 WALGREENS #7261 1934113 1669624250 DRYS PHARMACY 2803927 1942368352 THE NEBRASKA MED CENTER CLINIC PHCY 2813687 1184736431 OMNICARE OF NEBRASKA 3200247 1457366353 WALGREENS #4950 3200336 1346455680 RODEN-SMITH PHARMACY 3207241 1982621025 WAL-MART PHARMACY 10-0821 3207811 1073530127 WAL-MART PHARMACY 10-0549 3208041 1174538078 WALGREENS #7930 3208053 1083629984 WALGREENS #2349 3211935 1114255775 WALGREENS
    [Show full text]
  • CVS CAREMARK CORPORATION (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ⌧ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 29, 2007 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-01011 CVS CAREMARK CORPORATION (Exact name of Registrant as specified in its charter) Delaware 050494040 (State or other jurisdiction of (I.R.S. Employer Identification No.) incorporation or organization) One CVS Drive 02895 Woonsocket, Rhode Island (Zip Code) (Address of principal executive offices) (401) 765-1500 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: Common Stock, par value $0.01 per share New York Stock Exchange Title of each class Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes[X] No[ ] Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes[ ] No[X] Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • CVS CAREMARK CORP Mailing Address Business Address ONE CVS DR
    SECURITIES AND EXCHANGE COMMISSION FORM 10-K Annual report pursuant to section 13 and 15(d) Filing Date: 2010-02-26 | Period of Report: 2009-12-31 SEC Accession No. 0001193125-10-043086 (HTML Version on secdatabase.com) FILER CVS CAREMARK CORP Mailing Address Business Address ONE CVS DR. ONE CVS DR. CIK:64803| IRS No.: 050494040 | State of Incorp.:DE | Fiscal Year End: 1231 WOONSOCKET RI 02895 WOONSOCKET RI 02895 Type: 10-K | Act: 34 | File No.: 001-01011 | Film No.: 10640360 4017651500 SIC: 5912 Drug stores and proprietary stores Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2009 OR ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 001-01011 CVS CAREMARK CORPORATION (Exact name of Registrant as specified in its charter) Delaware 050494040 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One CVS Drive Woonsocket, Rhode Island 02895 (Address of principal executive offices) (Zip Code) (401) 765-1500 (Registrants telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: Common Stock, par value $0.01 per share New York Stock Exchange Title of each class Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Exchange Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]